Analyzing Inogen (NASDAQ:INGN) and LogicMark (NASDAQ:LGMK)

Inogen (NASDAQ:INGNGet Rating) and LogicMark (NASDAQ:LGMKGet Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Volatility and Risk

Inogen has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500. Comparatively, LogicMark has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500.

Institutional & Insider Ownership

95.9% of Inogen shares are owned by institutional investors. Comparatively, 7.7% of LogicMark shares are owned by institutional investors. 1.2% of Inogen shares are owned by company insiders. Comparatively, 3.6% of LogicMark shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Inogen and LogicMark’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Inogen $377.24 million 0.77 -$83.77 million ($3.66) -3.46
LogicMark $10.02 million 0.26 -$11.71 million N/A N/A

LogicMark has lower revenue, but higher earnings than Inogen.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Inogen and LogicMark, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inogen 0 2 1 0 2.33
LogicMark 0 0 0 0 N/A

Inogen presently has a consensus target price of $26.00, suggesting a potential upside of 105.37%. Given Inogen’s higher possible upside, equities research analysts plainly believe Inogen is more favorable than LogicMark.


This table compares Inogen and LogicMark’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Inogen -22.21% -8.72% -6.53%
LogicMark -88.42% -43.92% -37.13%


Inogen beats LogicMark on 8 of the 11 factors compared between the two stocks.

About Inogen

(Get Rating)

Inogen, Inc. is a medical technology company, which engages in the development, manufacture, and marketing of portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Its products include Inogen One G4 system, Inogen One G3 system, Inogen One G5 system, Inogen TAV, and Inogen at Home. The company was founded by Alison Perry, Alison K. Bauerlein, Brenton Taylor, and Byron Myers on November 27, 2001 and is headquartered in Goleta, CA.

About LogicMark

(Get Rating)

LogicMark, Inc. provides technology products and services for healthcare applications that enable the Internet of Things (IoT). It operates business in one segment-hardware and software security systems and applications. The firm develops and markets solutions for payment and IoT applications. Its technology products and solutions include MobileBio, a suite of biometric solutions that secure consumers’ mobile platforms, the Wocket, a next-generation smart wallet and the Flye, a digital credit card developed in collaboration with WorldVentures. The company was founded by Gino Miguel Pereira and David Charles Tunnell on February 8, 2012 and is headquartered Louisville, KY.

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with's FREE daily email newsletter.